Alzheimer's disease diagnosis based on gene selection and cross-tissue validation.

DeepFS achieves 89.45% accuracy and 0.9647 AUC in diagnosing Alzheimer's disease from brain tissue transcriptomic data.

• Why it matters: Early and accurate diagnosis of AD is essential for intervention, but current methods are invasive or costly, limiting large-scale screening and early detection efforts.
• What they did: The study developed DeepFS, a transcriptomic-based diagnostic framework with an automated gene selection module, and validated its performance on brain tissue and peripheral blood datasets, including single-nucleus RNA sequencing data.
• The result: DeepFS demonstrates high diagnostic accuracy and consistency across tissue types, providing a reliable tool that may guide future AD biomarker research and improve early diagnosis strategies.